NCT04893395

Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Auburn University · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the prevalence of veterans with major depressive disorder (MDD) who are being treated with a medication that has current Clinical Pharmacogenetics Implementation Consortium (CPIC) or Pharmacogenomics Knowledgebase (PharmGKB) actionable recommendations that have a pharmacogenomic variation that impacts the safety or efficacy of the subject medication.

Conditions

• Pharmacogenetics
• Depressive Disorder, Major
• Medication Therapy Management

Interventions

Type	Name	Description
OTHER	Pharmacogenomic Screening	First telehealth appointment: 1. Pharmacogenomics education and informed consent 2. Medical history 3. Sample collection Second telehealth appointment: 1. Results of pharmacogenomic testing 2. Utility and limitations of pharmacogenomic testing 3. Patient-specific potential impacts on current or future medication therapies 4. Answering of patient questions 5. Referral to mental health provider(s) for treatment-specific recommendations

Timeline

• Start date: 2021-09-01
• Primary completion: 2022-04-30
• Completion: 2022-12-31
• First posted: 2021-05-19
• Last updated: 2022-08-09

Locations

1 site across 1 country: United States